前列腺素E2对肿瘤微环境中髓源性抑制细胞的调控作用

doi:10.3760/cma.j.issn.1673422X.2017.03.006

摘要/Abstract

摘要： 髓源性抑制细胞（MDSC）是一群未成熟的骨髓异质性细胞，在肿瘤免疫耐受和免疫抑制中具有重要作用。近年越来越多的研究结果表明前列腺素E2（PGE2）与MDSC有着密不可分的关系，PGE2在肿瘤微环境中通过作用其相关受体，调控信号转导与转录激活因子3（STAT3）和蛋白激酶A等细胞信号通路及细胞因子的分泌，影响着MDSC的增殖、分化及功能。

关键词: 地诺前列酮, 骨髓, 细胞, 肿瘤

Abstract: Myeloidderived suppressor cells (MDSCs), a heterogeneous population of immature myeloid cells, play an important role in immune tolerance and immune suppression. In recent years, more and more research results show that the prostaglandin E2 (PGE2) has an inseparable relationship with MDSCs, and PGE2 through its relevant receptors, regulating signal transducer and activator of transcription 3 (STAT3) and protein kinase A cell signaling pathways and secretion cytokines in tumor microenvironment, affects the development, differentiation and function of MDSCs.

Key words: Dinoprostone, Bone marrow, Cells, Neoplasms

谢辉兰,张民皓,顾连兵,鲍红光. 前列腺素E2对肿瘤微环境中髓源性抑制细胞的调控作用[J]. 国际肿瘤学杂志, 2017, 44(3): 182-185.

Xie Huilan, Zhang Minhao, Gu Lianbing, Bao Hongguang. Regulation of myeloidderived suppressor cells by prostaglandin E2 in tumor microenvironment[J]. Journal of International Oncology, 2017, 44(3): 182-185.

参考文献

［1］ Kalinski P. Regulation of immune responses by prostaglandin E2［J］. J Immunol, 2012, 188(1): 21-28. DOI: 10.4049/jimmunol.1101029. ［2］ O′callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?［J］. Br J Pharmacol, 2015, 172(22): 5239-5250. DOI: 10.1111/bph.13331. ［3］ Liu B, Qu L, Yan S. Cyclooxygenase2 promotes tumor growth and suppresses tumor immunity［J］. Cancer Cell Int, 2015, 15: 106. DOI: 10.1186/s1293501502607. ［4］ Marvel D, Gabrilovich DI. Myeloidderived suppressor cells in the tumor microenvironment: expect the unexpected［J］. J Clin Invest, 2015, 125(9): 3356-3364. DOI: 10.1172/JCI80005. ［5］ Dolcetti L, Peranzoni E, Ugel S, et al. Hierarchy of immunosuppressive strength among myeloidderived suppressor cell subsets is determined by GMCSF［J］. Eur J Immunol, 2010, 40(1): 22-35. DOI: 10.1002/eji.200939903. ［6］ Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloidderived suppressor cells in tumorbearing mice［J］. J Immunol, 2008, 181(8): 5791-5802. ［7］ Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumorinduced myeloidderived suppressor cell subpopulations with distinct T cellsuppressive activity［J］. Blood, 2008, 111(8): 4233-4244. DOI: 10.1182/blood200707099226. ［8］ Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloidderived suppressor cells in cancer patients［J］. Cancer Immunol Immunother, 2012, 61(2): 255-263. DOI: 10.1007/s0026201111619. ［9］ Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloidderived suppressor cells［J］. Cancer Res, 2007, 67(9): 4507-4513. DOI: 10.1158/00085472.CAN064174. ［10］ Xiang X, Poliakov VK, Liu C, et al. Induction of myeloidderived suppressor cells by tumor progression by inducing myeloidderived suppressor cells［J］. Int J Cancer, 2009, 124(11): 2621-2633. ［11］ Lee H, Pal SK, Reckamp K, et al. STAT3: a target to enhance antitumor immune response［J］. Curr Top Microbiol Immunol, 2011, 344: 41-59. DOI: 10.1007/82_2010_51. ［12］ Mao Y, Poschke I, Wennerberg E, et al. Melanomaeducated CD14+ cells acquire a myeloidderived suppressor cell phenotype through COX2dependent mechanisms［J］. Cancer Res, 2013, 73(13): 3877-3887. DOI: 10.1158/00085472.CAN124115. ［13］ Liu Q, Zhang M, Jiang X, et al. miR223 suppresses differentiation of tumorinduced CD11b+ Gr1+ myeloidderived suppressor cells from bone marrow cells［J］. Int J Cancer, 2011, 129(11): 2662-2673. DOI: 10.1002/ijc.25921. ［14］ Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA223［J］. Nature, 2008, 451(7182): 1125-1129. DOI: 10.1038/nature06607. ［15］ Rong Y, Yuan CH, Qu Z, et al. Doxorubicin resistant cancer cells activate myeloidderived suppressor cells by releasing PGE2［J］. Sci Rep, 2016, 6: 23824. DOI: 10.1038/srep23824. ［16］ Tecchio C, Cassatella MA. Neutrophilderived chemokines on the road to immunity［J］. Semin Immunol, 2016, 28(2): 119-128. DOI: 10.1016/j.smim.2016.04.003. ［17］ Obermajer N, Muthuswamy R, Odunsi K, et al. PGE(2)induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment［J］. Cancer Res, 2011, 71(24): 7463-7470. DOI: 10.1158/00085472.CAN112449. ［18］ Fujita M, Kohanbash G, FellowsMayle W, et al. COX2 blockade suppresses gliomagenesis by inhibiting myeloidderived suppressor cells［J］. Cancer Res, 2011, 71(7): 2664-2674. DOI: 10.1158/00085472.CAN103055. ［19］ Kim R, Emi M, Tanabe K, et al. Tumordriven evolution of immunosuppressive networks during malignant progression［J］. Cancer Res, 2006, 66(11): 5527-5536. DOI: 10.1158/00085472.CAN054128. ［20］ Zhang Y, Liu Q, Zhang M, et al. Fas signal promotes lung cancer growth by recruiting myeloidderived suppressor cells via cancer cellderived PGE2［J］. J Immunol, 2009, 182(6): 3801-3808. DOI: 10.4049/jimmunol.0801548. ［21］ Pyzer AR, Cole L, Rosenblatt J, et al. Myeloidderived suppressor cells as effectors of immune suppression in cancer［J］. Int J Cancer, 2016, 139(9): 1915-1926. DOI: 10.1002/ijc.30232. ［22］ Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloidderived suppressor cells［J］. Oncoimmunology, 2016, 5(2): e1004983. DOI: 10.1080/2162402X.2015.1004983. ［23］ Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase Ⅰ in myeloid suppressor cells is induced by COX2 in lung carcinoma［J］. J Exp Med, 2005, 202(7): 931-939. DOI: 10.1084/jem.20050715. ［24］ Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention by cyclooxygenase2 inhibition reduces immature myeloid suppressor cell expansion［J］. Int Immunopharmacol, 2007, 7(2): 140-151. DOI: 10.1016/j.intimp.2006.09.021. ［25］ Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloidderived suppressor cells from normal human peripheral blood mononuclear cells［J］. J Immunol, 2010, 185(4): 2273-2284. DOI: 10.4049/jimmunol.1000901. ［26］ Huang B, Pan PY, Li Q, et al. Gr1+CD115+ immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and Tcell anergy in tumorbearing host［J］.Cancer Res, 2006, 66(2): 1123-1131. ［27］ Mao Y, Sarhan D, Steven A, et al. Inhibition of tumorderived prostaglandine2 blocks the induction of myeloidderived suppressor cells and recovers natural killer cell activity［J］. Clin Cancer Res, 2014, 20(15): 4096-4106. DOI: 10.1158/10780432.CCR140635. ［28］ Veltman JD, Lambers ME, van Nimwegen M, et al. COX2 inhibition improves immunotherapy and is associated with decreased numbers of myeloidderived suppressor cells in mesothelioma. Celecoxib influences MDSC function［J］. BMC Cancer, 2010, 10: 464. DOI: 10.1186/1471240710464. ［29］ Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloidderived suppressor cells［J］. Blood, 2011, 118(20): 5498-5505. DOI: 10.1182/blood201107365825. ［30］ Obermajer N, Kalinski P. Generation of myeloidderived suppressor cells using prostaglandin E2［J］. Transplant Res, 2012, 1(1): 15. DOI: 10.1186/20471440115.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.